Nuc Med - Theranostics - Innovation. Embracing Change.

Joined April 2022
61 Photos and videos
Ken Herrmann retweeted
Understanding #RadiopharmaceuticalTherapy in #ProstateCancer: From Mechanism to Clinical Practice. Radiopharmaceutical therapy is rapidly reshaping the treatment landscape in advanced prostate cancer, bringing new opportunities—and new clinical questions—around patient selection, treatment sequencing, safety, mechanism of action, and future integration. In this exclusive UroToday clinical conversation series, leading experts in #MedicalOncology, #RadiationOncology, #NuclearMedicine, and TranslationalScience explore the evolving role of radiopharmaceutical therapy across the prostate cancer continuum. Through practical, peer-to-peer discussions, this series examines today’s treatment landscape, the biological and mechanistic distinctions between emerging approaches, real-world considerations for clinical decision-making, and where the next wave of innovation may take the field. #WatchNow > bit.ly/43grc3t #MichaelMorris @DrRanaMcKay @ProfKHerrmann @PrafulRavi1 @boothe_dustin @PhillipKooMD @nhbander @TDorffOnc @DrPhilKantoff @ConvergentRx #NealShore
6
9
641
Ken Herrmann retweeted
….So it begins! #ASCO26 #belong
1
12
59
2,187
Ken Herrmann retweeted
The⚽️tournament @ASCO is back: Registration is open--see below with @cdanicas for all what you need to know! #ASCO25 @OncoAlert @FAndreMD @jrgralow
🎯🔥⚽️the most funky, friendly, fashioned social event is coming again!! 💪💪 @ASCO @ASCOPres 🚀 The World #ASCO26 football Cup! @DrChoueiri @FAndreMD 📆 Saturday May 30th (6.00-10.00PM) Registration is open Contact: cdanicas@gmail.com 🙌🙌Brasil, Argentina, Colombia,Peru and USA are confirmed🏃‍♂️🏃‍♂️ The latest versions were a lot of fun. 😎 Don't miss it and sign up!🔥 With a rock stars @DrChoueiri !! @OncoAlert @aaoncoclinica @SoaresAndrey @myESMO @raymanneh @GuardConsortium @DrFelixGuerrero
8
29
3,556
Ken Herrmann retweeted
Seeing is believing. CcRCC has the most complex metastatic patterns and many patients are misdiagnosed in routine clinical practice. CD70 PET is changing the landscape in China, many patients benefit from the imaging clinical trials. Need to develop CD70 therapeutic drugs!
Now online in @CD_AACR: [18F]RCCB6 PET/CT in Diagnosing Clear Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging - by Qianyun Wu, Shuxian An, @ArturoChiti, Gang Huang, Jianjun Liu, @Weijun_Wei89, and colleagues
3
8
1,022
Ken Herrmann retweeted
First images from the GE Omni 128 cm Total Body PET/CT 🚀 The new scanner detected a <5 mm local recurrence of prostate cancer missed by standard PSMA PET/CT - despite 79% shorter acquisition ⏱️ Delayed imaging boosted lesion uptake and informed dose-painted salvage RT 🎯 @JournalofNucMed @PeterMacCC @declangmurphy @_ShankarSiva jnm.snmjournals.org/content/…
5
46
174
21,363
Ken Herrmann retweeted
16
15
32
6,474
Ken Herrmann retweeted
First total-body kinetics study of ¹⁸F-flurpiridaz in healthy volunteers at rest and feasibility of simplified quantitative strategies. ow.ly/OURu50YGHUY #NuclearMedicine #PETscan #MolecularImaging
1
7
12
696
Ken Herrmann retweeted
A reminder that #APCCC26 🇨🇭is coming in Late April and is OPEN TO EVERYONE, not just the Panel members and 👉️ REGISTER HERE: buff.ly/XpCWPdR 🚨 Enjoy 20% off when registering for both APCCC & IPCS 2026 Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 Event Details: 📍 Palazzo Congressi, Lugano, Switzerland 🎟️ Register here 🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards. Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! @Silke_Gillessen & @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun Ping @nataliagandur @OncoAlert 🚨
5
16
984
Ken Herrmann retweeted
PCWG4 is launched: ascopubs.org/doi/10.1200/JCO… Imaging response is expanded to include PSMA PET/CT. In the future, patient may have 1 scan (PSMA PET with CT) rather than two scans (CT bone scan). All my nuclear colleagues will be happy to retire the bone scan. @AarmstrongDuke
2
16
42
3,734
Ken Herrmann retweeted
Just Published at @JCO_ASCO and out for #GU26 POSTER NOW BEING PRESENTED 11:30-12:45pm ABSTRACT 162 Poster Bd E17 (Please Visit) Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 👉ascopubs.org/doi/10.1200/JCO… Here is Dr Michael Morris🇺🇸from @MSKCancerCenter to tell us more #ProstateCancer @DrRanaMcKay Michael J. Morris @EAntonarakis @AarmstrongDuke @mishabeltran @drlouiseemmett @ProfKHerrmann @DrMHofman @JoshLangMD @CaPsurvivorship @Cpaller @cnsternberg
6
13
765
Ken Herrmann retweeted
Just Published at @JCO_ASCO and out for #GU26 Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 ascopubs.org/doi/10.1200/JCO… Here is Dr Andrew Armstrong🇺🇸 @AarmstrongDuke to tell us more #ProstateCancer @DrRanaMcKay Michael J. Morris @EAntonarakis @mishabeltran @drlouiseemmett @ProfKHerrmann @DrMHofman @JoshLangMD @CaPsurvivorship @Cpaller @cnsternberg
6
14
692
Ken Herrmann retweeted
The #OncoAlertTopTweet 🚨DAY ONE #GU26 #APCCC26 🇨🇭 is open to everyone (not just panel members!) and is on April 30-May 2nd in Lugano EARLY REGISTRATION CLOSES February 28, 2026 👉 REGISTER HERE: buff.ly/XpCWPdR Join global experts in advanced #ProstateCancer at the Advanced Prostate Cancer Consensus Conference in Lugano (Palazzo Congressi) for two days of high-level debates addressing real-world clinical questions where evidence is limited, shaping future standards of care published in European Urology while creating opportunities for the next generation of leaders; enjoy 20% off when registering for both APCCC & IPCS 2026 @Silke_Gillessen @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrunPing @nataliagandur @OncoAlert
Colleagues at #GU26 ,A reminder that #APCCC26 🇨🇭is coming in 2026 This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY REGISTRATION is up until February 28, 2026 👉️ REGISTER HERE: buff.ly/XpCWPdR Only 🔟 days left until the Early Bird deadline (28 February 2026) Enjoy 20% off when registering for both APCCC & IPCS 2026 Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 Event Details: 📍 Palazzo Congressi, Lugano, Switzerland 🎟️ Register here 🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards. Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! @Silke_Gillessen & @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun Ping @nataliagandur @OncoAlert 🚨
12
16
1,867
Ken Herrmann retweeted
2 Dec 2025
Pretherapy ¹²⁴I PET/CT dosimetry shows that metastatic lesions absorb higher radiation doses after thyroid hormone withdrawal than after recombinant human TSH injection. ow.ly/7Wn550XqIXE #NuclearMedicine #ThyroidCancer #PETscan @ProfKHerrmann
1
11
22
1,602
177Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer jnm.snmjournals.org/content/… This invited perspective discusses a patient with low-volume metastatic hormone-sensitive #ProstateCancer who declined standard ADT-based therapies and instead received first-line off-label Lu-PSMA monotherapy, achieving a partial response with minimal toxicity. Although the case is intriguing and reflects growing interest in earlier PSMA-targeted treatment, the authors stress that it represents a single, highly selected patient and does not outweigh strong evidence supporting ADT-based doublet or triplet regimens as the proven standard of care. They highlight key limitations—modest PSA response, short follow-up, uncertain generalizability, mechanistic uncertainties, and ethical concerns about off-label use—and emphasize that Lu-PSMA monotherapy should not be used outside clinical trials. Overall, while patients may wish to avoid ADT side effects, there is no evidence that ADT-free strategies preserve survival, and prospective studies are essential before altering current practice. @ProfHadaschik @Silke_Gillessen Oliver Sartor @OncoAlert 🚨 @AOmlin @weoncologists
1
14
29
2,755
Ken Herrmann retweeted
First in the world @GEHealthCare Omni 128cm Total Body PET just installed at @PeterMacCC ... serial number 001. 50 times the sensitivity of our existing PET scanner enabling faster scanning with less radiation and greater clarity. Our new centre seamlessly integrates pre-clinical imaging, state-of-the-art radiopharmaceutical sciences to enable rapid translation from laboratory to clinic. Thank-you to @ACRF_ @NIFAus @UniMelb
A major step forward for precision medicine today. Peter Mac has installed cutting-edge @GEHealthCare total body PET/CT technology — supported by $15M in new grants and funding.
1
6
44
6,017
Ken Herrmann retweeted
Are you ready for radioligand therapy? Join the next #ESMOOnAir webinar part of the Therapeutic Landscapes series: - Science, clinical trials & system readiness for RLT - Live expert Q&A 🔗 ow.ly/b4Es50XnBxm #Oncology #Radiotheranostics #CancerCare #RLT #MedicalEducation
2
4
14
1,885
Ken Herrmann retweeted
19 Oct 2025
Associations between quantitative baseline 68Ga-PSMA-11 PET parameters and 177Lu-PSMA-617 efficacy in the #PSMAfore study. Presentation by @ProfKHerrmann. #ESMO25 written coverage by @zklaassen_md > bit.ly/497R0mz @myESMO
8
14
893
Ken Herrmann retweeted
19 Oct 2025
Scaling up capacity to deliver radioligand therapeutics. Presentation by @ProfKHerrmann. #ESMO25 written coverage by @chavarriagaj > bit.ly/4nUQWLv @myESMO
6
8
668
Ken Herrmann retweeted
20 Oct 2025
PSMA PET scans are packed with potential, but making sense of all that data? That’s where automation steps in. @ProfKHerrmann shares insights on how PSMA-TTV could unlock new levels of precision in patient selection for radioligand therapy🔓 #ESMO25 #ProstateCancer #MedX
2
3
213

14
27
5,840